Susquehanna International Group, LLP Arcturus Therapeutics Holdings Inc. Put Options Transaction History

Susquehanna International Group, LLP

  • $688 Billion
  • Q2 2025

Put Options

12 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2025

Aug 14, 2025
SELL
$8.91 - $14.41 $46,332 - $74,932
-5,200 Reduced 15.76%
27,800 $361,000
Q1 2025

May 14, 2025
SELL
$10.59 - $20.83 $210,741 - $414,516
-19,900 Reduced 37.62%
33,000 $349,000
Q4 2024

Feb 14, 2025
SELL
$14.82 - $25.48 $309,738 - $532,532
-20,900 Reduced 28.32%
52,900 $897,000
Q3 2024

Nov 14, 2024
BUY
$18.08 - $25.38 $153,680 - $215,730
8,500 Added 13.02%
73,800 $1.71 Million
Q2 2024

Aug 15, 2024
SELL
$24.35 - $44.39 $2.32 Million - $4.22 Million
-95,100 Reduced 59.29%
65,300 $1.59 Million
Q1 2024

May 07, 2024
BUY
$31.23 - $42.99 $584,001 - $803,913
18,700 Added 13.2%
160,400 $5.42 Million
Q4 2023

Feb 14, 2024
BUY
$17.71 - $32.97 $380,765 - $708,855
21,500 Added 17.89%
141,700 $4.47 Million
Q3 2023

Nov 14, 2023
SELL
$25.44 - $37.35 $2 Million - $2.94 Million
-78,800 Reduced 39.6%
120,200 $3.07 Million
Q2 2023

Aug 11, 2023
BUY
$23.94 - $32.36 $1.78 Million - $2.4 Million
74,300 Added 59.58%
199,000 $5.71 Million
Q1 2023

May 16, 2023
BUY
$14.72 - $23.97 $647,680 - $1.05 Million
44,000 Added 54.52%
124,700 $2.99 Million
Q4 2022

Feb 14, 2023
SELL
$14.14 - $23.06 $533,078 - $869,362
-37,700 Reduced 31.84%
80,700 $1.37 Million
Q3 2022

Nov 14, 2022
SELL
$13.05 - $22.13 $388,890 - $659,474
-29,800 Reduced 20.11%
118,400 $1.76 Million

Others Institutions Holding ARCT

# of Institutions
169
Shares Held
25.9M
Call Options Held
289K
Put Options Held
109K
View Full List

About Arcturus Therapeutics Holdings Inc.

ARCT Quotes by TradingView
  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $396M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email